Risk factors and outcomes of Stenotrophomonas maltophilia bacteraemia: a comparison with bacteraemia caused by Pseudomonas aeruginosa and Acinetobacter species.
Stenotrophomonas maltophilia (SM) is an important nosocomial pathogen that exhibits intrinsic resistance to various antimicrobial agents. However, the risk factors for SM bacteraemia have not been sufficiently evaluated. From January 2005 to September 2012, we retrospectively compared the clinical backgrounds and outcomes of SM bacteraemic patients (SM group) with those of bacteraemic patients due to Pseudomonas aeruginosa (PA group) or Acinetobacter species (AC group). DNA genotyping of the SM isolates using the Diversilab system was performed to investigate the genetic relationships among the isolates. The SM, PA, and AC groups included 54, 167, and 69 patients, respectively. Nine of 17 patients in the SM group receiving trimethoprim-sulfamethoxazole prophylaxis developed SM bacteraemia. Independent risk factors for SM bacteraemia were the use of carbapenems and antipseudomonal cephalosporins and SM isolation within 30 days prior to the onset of bacteraemia. Earlier SM isolation was observed in 32 of 48 patients (66.7%) with SM bacteraemia who underwent clinical microbiological examinations. Of these 32 patients, 15 patients (46.9%) had the same focus of bacteraemia as was found in the previous isolation site. The 30-day all-cause mortality rate among the SM group (33.3%) was higher than that of the PA group (21.5%, p = 0.080) and the AC group (17.3%, p = 0.041). The independent factor that was associated with 30-day mortality was the SOFA score. DNA genotyping of SM isolates and epidemiological data suggested that no outbreak had occurred. SM bacteraemia was associated with high mortality and should be considered in patients with recent use of broad-spectrum antibiotics or in patients with recent isolation of the organism.
Kyoto University Graduate School of Medicine, Department of Clinical Laboratory Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan.
Go
G
Hotta
Kyoto University Graduate School of Medicine, Department of Clinical Laboratory Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan.
Yasufumi
Y
Matsumura
Kyoto University Graduate School of Medicine, Department of Clinical Laboratory Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan.
Karin
K
Kato
Kyoto University Graduate School of Medicine, Department of Clinical Laboratory Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan.
Satoshi
S
Nakano
Kyoto University Graduate School of Medicine, Department of Clinical Laboratory Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan.
Tomoyuki
T
Yunoki
Kyoto University Graduate School of Medicine, Department of Clinical Laboratory Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan.
Masaki
M
Yamamoto
Kyoto University Graduate School of Medicine, Department of Clinical Laboratory Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan.
Miki
M
Nagao
Kyoto University Graduate School of Medicine, Department of Respiratory Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan.
Yutaka
Y
Ito
Kyoto University Graduate School of Medicine, Department of Clinical Laboratory Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan.
Shunji
S
Takakura
Kyoto University Graduate School of Medicine, Department of Clinical Laboratory Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan.
Satoshi
S
Ichiyama
D000150:Acinetobacter / Q000187:drug effects / Q000472:pathogenicity*; D000151:Acinetobacter Infections / Q000188:drug therapy; D000328:Adult; D000368:Aged; D016470:Bacteremia / Q000382:microbiology* / Q000517:prevention & control; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009026:Mortality; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000472:pathogenicity*; D012189:Retrospective Studies; D012307:Risk Factors; D020615:Stenotrophomonas maltophilia / Q000187:drug effects / Q000472:pathogenicity / Q000276:immunology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D015662:Trimethoprim, Sulfamethoxazole Drug Combination